Amicus Therapeutics, Inc. (FOLD) Report Analysis
Corporate Events
Amicus Therapeutics, Inc. has filed a Shelf Registration in the amount of $51.3 million.
2022-06-10 00:00:00
Amicus Therapeutics, Inc. has filed a Shelf Registration in the amount of $51.3 million. Security Name: Common Stock Securities Offered: 6,000,000 Transaction Features: ESOP Related Offering
Amicus Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 11:20 AM
2022-06-08 16:18:00
Amicus Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 11:20 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Amicus Therapeutics, Inc. Presents at BIO International Convention 2022, Jun-13-2022
2022-05-15 00:00:00
Amicus Therapeutics, Inc. Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Paul Howard, Senior Director of Public Policy.
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
2022-05-10 20:01:00
Amicus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA. The revised PDUFA action dates for miglustat and cipaglucosidase alfa are August 29, 2022 and October 29, 2022, respectively. The Company continues to expect the FDA to approve the applications together. The FDA extended the PDUFA dates to allow additional time to review information submitted by the Company as part of its ongoing reviews. The extension of the review timeline was not related to requests for any additional clinical data. The company also expects that the additional time will allow for the completion of the pre-license approval inspections necessary at the WuXi Biologics manufacturing site in China. Previously, the FDA granted Breakthrough Therapy Designation to AT-GAA for the treatment of late-onset Pompe disease based on clinical efficacy results from the Phase 1/2 clinical study. In the European Union, the Marketing Authorization Applications were validated in the fourth quarter of 2021 and the Committee for Medicinal Products for Human Use (CHMP) opinion is expected in late 2022. AT-GAA is an investigational two-component therapy that consists of cipaglucosidase alfa (ATB200), a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly bis-phosphorylated mannose-6 phosphate (bis-M6P) glycans, to enhance uptake into cells, administered in conjunction with miglustat (AT2221), a stabilizer of cipaglucosidase alfa. In preclinical studies, AT-GAA was associated with increased levels of the mature lysosomal form of GAA and reduced glycogen levels in muscle, alleviation of the autophagic defect and improvements in muscle strength. In addition, Amicus is enrolling an open-label, uncontrolled, multicenter study to evaluate the PK, safety, efficacy, and PD of AT-GAA in pediatric patients aged 0 to 18 years with LOPD (ATB200-04). More information, including a list of participating sites, is available at www.clinicaltrials.gov: NCT03911505.
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022
2022-05-09 11:00:00
Amicus Therapeutics, Inc. provided revenue guidance for the full year of 2022. For the year, the company expects total Galafold revenue of $350 million to $365 million at constant exchange rates. Double-digit revenue growth between 15 and 20% at CER1 in 2022 is expected to be driven by continued underlying demand from both switch and naïve patients, geographic expansion, the continued diagnosis of new Fabry patients and commercial execution across all major markets, including the U.S., EU, U.K., and Japan. Applying average April 2022 exchange rates, the negative currency impact on full-year 2022 Galafold reported sales would be approximately 6%.
Amicus Therapeutics, Inc. Presents at BioPartnering Conference, May-11-2022 10:30 AM
2022-05-06 06:25:00
Amicus Therapeutics, Inc. Presents at BioPartnering Conference, May-11-2022 10:30 AM. Speakers: Paul I. Howard, Senior Director of Public Policy.
Amicus Therapeutics, Inc., Annual General Meeting, Jun 09, 2022
2022-04-26 20:39:00
Amicus Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 09:00 US Eastern Standard Time.
Amicus Therapeutics, Inc. - Shareholder/Analyst Call
2022-04-26 20:39:00
Annual Meeting of Stockholders
Amicus Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022
2022-04-26 11:01:00
Amicus Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022
Amicus Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022
2022-04-26 11:01:00
Amicus Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022
Amicus Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022
2022-04-12 05:58:00
Amicus Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 . Venue: Barcelona, Spain. Speakers: Jill Weimer, Chief Science Officer.
Amicus Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:00 PM
2022-03-22 05:03:00
Amicus Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:00 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Bradley L. Campbell, President, COO & Director, Jeffrey P. Castelli, Chief Development Officer.
BioNJ Inc., BioPartnering Conference, May 09, 2022 through May 13, 2022
2022-03-08 19:00:00
BioNJ Inc., BioPartnering Conference, May 09, 2022 through May 13, 2022.
Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022
2022-02-26 07:53:00
Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022. Venue: Barcelona, Spain.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Amicus Therapeutics, Inc. Presents at Patient Advocacy Summit, Dec-09-2021 11:35 AM
2021-12-07 06:02:00
Amicus Therapeutics, Inc. Presents at Patient Advocacy Summit, Dec-09-2021 11:35 AM. Speakers: Nita Patel, Executive Director, Patient & Professional Advocacy.
Amicus Therapeutics, Inc. Presents at BioFlorida Conference, Dec-09-2021 08:30 AM
2021-12-07 04:14:00
Amicus Therapeutics, Inc. Presents at BioFlorida Conference, Dec-09-2021 08:30 AM. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States. Speakers: John F. Crowley, Chairman & CEO.
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
2021-12-03 12:00:00
Amicus Therapeutics, Inc. announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease. Validation of the application confirms the submission is accepted, and the EMA’s centralized procedure with Committee for Medicinal Products for Human Use (CHMP)’s assessment begins. The MAAs were submitted to the EMA based on the evaluation of the effects of AT-GAA in adults living with Pompe disease and its safety profile, which include data from the Phase 1/2 and Phase 3 PROPEL studies, as well as data from the long-term open-label extension study.
Amicus Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 08:50 AM
2021-11-24 07:11:00
Amicus Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 08:50 AM.
The Lancet Neurology Publishes Amicus Therapeutics, Inc.'s Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
2021-11-18 12:00:00
Amicus Therapeutics announced that the data from the Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of care, alglucosidase alfa, were published online in The Lancet Neurology. The manuscript includes data on the primary and key secondary endpoints, which were previously reported, as well as additional secondary endpoints. Based on the outcomes observed in the key domains of Pompe disease (muscle strength, pulmonary and motor function, patient-reported outcomes and biomarkers), the peer reviewed results determined the PROPEL data showed clinically meaningful improvements over standard of care, even among those who had been receiving approved therapy for at least 2 years, a subgroup that has been shown to plateau or decline after several years on treatment. AT-GAA is a two-component therapy consisting of cipaglucosidase alfa, an enhanced phosphorylated enzyme and miglustat, an enzyme stabilizer, thereby providing a different mechanism of action compared with alglucosidase alfa. The U.S. Food and Drug Administration (FDA) previously granted Breakthrough Therapy designation for AT-GAA and accepted for review the Biologics License Application (BLA) and the New Drug Application (NDA). The FDA has set a Prescription Drug User Fee Act action date of May 29, 2022 for the NDA and July 29, 2022 for the BLA. In the EU, the Marketing Authorization Applications for AT-GAA have been submitted in the fourth quarter of 2021.
Amicus Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 08:00 AM
2021-11-11 12:05:00
Amicus Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 08:00 AM. Venue: New York, New York, United States.
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022
2021-11-09 17:12:00
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.
Amicus Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2021
2021-11-09 12:08:00
Amicus Therapeutics, Inc. reiterated revenue guidance for the full year 2021. For the period, the company anticipates total Galafold revenue of $300 million to $315 million.
Amicus Therapeutics, Inc. has filed a Shelf Registration in the amount of $234.381134 million.
2021-11-09 00:00:00
Amicus Therapeutics, Inc. has filed a Shelf Registration in the amount of $234.381134 million. Security Name: Common Stock Securities Offered: 19,646,365
Amicus Therapeutics, Inc. to Report Q3, 2021 Results on Nov 09, 2021
2021-11-03 11:00:00
Amicus Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 09, 2021
Amicus Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021
2021-11-03 11:00:00
Amicus Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021
Amicus Therapeutics, Inc. announced that it has received $199.916499 million in funding from Perceptive Advisors LLC, Redmile Group, LLC, The Invus Group, LLC, Avoro Capital Advisors LLC, Sphera Funds Management Ltd, Janus Capital Management LLC, and other investors
2021-10-13 00:00:00
On October 13, 2021, Amicus Therapeutics, Inc. closed the transaction. The transaction included participation from 9 investors pursuant to exemption provided under regulation D.
BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021
2021-10-01 16:14:00
BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States.
Amicus Therapeutics, Inc. Announces Executive Changes
2021-09-29 13:28:00
In connection with the Business Combination, Amicus Therapeutics, Inc. announced John F. Crowley, who has served as a Director, Chairman and Chief Executive Officer of the Company since February 2010 and Chief Executive Officer since January 2005 (except for a period from April 2011 through August 2011 during which time he served as Executive Chairman), will resign as Director of the company. Effective September 29, 2021, Ms. Prout will no longer serve as Principal Accounting Officer of the Company as Daphne Quimi, Chief Financial Officer, will serve as both Principal Financial Officer and Principal Accounting Officer. The Company has also agreed to enter into a Strategic Advisor Agreement with John F. Crowley (the Strategic Advisor Agreement") in connection with the consummation of the Business Combination, pursuant to which, following the Closing, Mr. Crowley will provide services to the Company as Chairman Emeritus and Chief Strategic Advisor (or in such other position as may be mutually agreed upon by the parties) for an initial term of two years (which term may be extended for an additional year by mutual agreement). In connection with the Business Combination, Samantha Prout, who has served as Vice President and Global Controller since March of 2020, and Principal Accounting Officer of the Company since June of 2018, will resign as Vice President and Global Controller and has agreed to enter into an employment agreement with New Caritas at the Closing pursuant to which Ms. Prout will become the SVP Finance, Principal Accounting Officer & Principal Financial Officer of New Caritas effective as of, and contingent upon, the Closing. Effective September 29, 2021, Ms. Prout will no longer serve as Principal Accounting Officer of the Company as Daphne Quimi, Chief Financial Officer, will serve as both Principal Financial Officer and Principal Accounting Officer. Effective September 28, 2021, Hung Do, who has served as Chief Science Officer of the Company since July 2015, entered into amendment (the Do Amendment") to his employment agreement, dated February 18, 2020. Under the terms of the Do Amendment, Dr. Do will no longer serve as the Company's Chief Scientific Officer but will be named Chief Scientific Advisor (CSA").
Amicus Therapeutics, Inc. Announces Resignation of John F. Crowley as Chief Executive Officer
2021-09-29 13:28:00
On September 29, 2021, Amicus Therapeutics, Inc. (the “Company”), ARYA Sciences Acquisition Corp. IV, Amicus GT Holdings, LLC, and Caritas Therapeutics, LLC entered into a Business Combination Agreement. In connection with the Business Combination, John F. Crowley, who has served as a Director, Chairman and Chief Executive Officer of the Company since February 2010 and Chief Executive Officer since January 2005 (except for a period from April 2011 through August 2011 during which time he served as Executive Chairman), will resign as Chief Executive Officer and Director of the Company and is expected to enter into an employment agreement with New Caritas pursuant to which he will become the Chief Executive Officer of New Caritas effective as of, and contingent upon, the Closing. Mr. Crowley is also expected to be nominated to serve as a director of New Caritas.
U.S. FDA Accepts Filings for Amicus Therapeutics, Inc.’ AT-GAA for the Treatment of Pompe Disease
2021-09-29 10:30:00
Amicus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease. Pompe disease is a rare genetic disease that causes premature death and has a debilitating effect on people’s lives. The U.S. represents the single largest geography for Amicus to positively impact the lives of people with Pompe disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of May 29, 2022 for the NDA and July 29, 2022 for the BLA. The BLA and NDA are based on the evaluation of the effects of AT-GAA in Pompe disease patients and its safety profile, which include data from the Phase 1/2 and Phase 3 PROPEL studies as well as data from the open-label extension study.
Amicus Therapeutics, Inc., ARYA Sciences Acquisition Corp IV - M&A Call
2021-09-29 10:30:00
To discuss the transaction
Amicus Therapeutics, Inc. announced that it expects to receive $199.916499 million in funding from Perceptive Advisors LLC, Redmile Group, LLC, The Invus Group, LLC, Avoro Capital Advisors LLC, Sphera Funds Management Ltd, Janus Capital Management LLC, and other investors
2021-09-29 00:00:00
Amicus Therapeutics, Inc. announced it has entered into subscription agreements for private placement of 11,296,660 common shares for $10.18 per share for gross proceeds of $114,999,998.8 and 8,349,705 pre-funded warrants at a purchase price of $10.17 per pre-funded warrant for gross proceeds of $84,916,499.85; for an aggregate gross proceeds of $199,916,498.65 on September 29, 2021. The transaction will include participation from funds managed by Redmile Group, LLC including Redmile Capital Offshore Fund (Erisa), Ltd., Redco II Master Fund, L.P. and Redmile Capital Fund, LP, for 8,349,705 pre-funded warrants for $84,916,499.85, Perceptive Life Sciences Master Fund, Ltd., a fund managed by Perceptive Advisors LLC, for 3,438,114 common shares for $10.18 per share for proceeds of $35,000,000.52, Avoro Life Sciences Fund LLC, a fund managed by Avoro Capital Advisors LLC for 3,929,27 shares for $39,999,999.14 and other investors. The transaction was approved by the board of directors of the company. The purchase agreements for the sale of pre-funded warrants, and for common shares subscribed by Perceptive Advisors LLC will provide for a lock-up period of nine months while for other subscribers, will provides for a lock-up period of 60 days. The issuance of the common stock and the pre-funded warrants to purchase 8,349,705 shares of common stock is exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, or Regulation D thereunder. Each Pre-Funded Warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance at the option of each holder and is exercisable into one common share each. The minimum investment accepted is $2,149,996 from any outside investor.
ARYA Sciences Acquisition Corp IV announced that it expects to receive $201.5 million in funding from a group of investors
2021-09-29 00:00:00
ARYA Sciences Acquisition Corp IV announced it has entered into subscription agreements for private placement of 20,150,000 common shares for $10 per share for gross proceeds of $201,500,000 on September 29, 2021. The transaction will include participation from Amicus Therapeutics, Inc. for $50,000,000, Perceptive Life Sciences Master Fund, Ltd., a fund managed by Perceptive Advisors LLC, Redmile Group, LLC and certain additional third party investors. The transaction has been approved by the board of directors of the company. The par value of the shares to be issued is $0.0001 per share. The subscription agreements provide that company will grant the investors certain customary registration rights. Completion of the transaction, which is expected in the fourth quarter of 2021 or early 2022, is subject to approval of company's shareholders. The company will incur expenses up to a maximum of $25,000,000.
Amicus Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 03:30 PM
2021-09-03 11:28:00
Amicus Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 03:30 PM. Venue: New Windsor, United States.
Amicus Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 11:45 AM
2021-09-03 11:28:00
Amicus Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 11:45 AM. Speakers: Bradley L. Campbell, President, COO & Director.
Amicus Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 08:40 AM
2021-09-03 11:28:00
Amicus Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 08:40 AM. Venue: New York, United States.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Amicus Therapeutics Provides Financial Guidance for the Full Year of 2021
2021-08-05 11:00:00
Amicus Therapeutics, Inc. provided financial guidance for the full year of 2021. For the full-year 2021, the Company anticipates total Galafold revenue of $300 million to $315 million. Double-digit revenue growth in 2021 is expected to be driven by continued operational growth and commercial execution across all major markets, including the U.S., EU, U.K. and Japan.
Amicus Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 09:00 AM
2021-08-04 11:00:00
Amicus Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 09:00 AM. Speakers: Andrew Faughnan, Senior Director of Investor Relations, Bradley L. Campbell, President, COO & Director, Jeffrey P. Castelli, Chief Development Officer, Jillian Kizmann, IR.
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
2021-08-02 11:00:00
Amicus Therapeutics announced the European Commission has approved Galafold® (migalastat) for use in adolescents aged 12 to <16 years weighing = 45 kg with a confirmed diagnosis of Fabry disease and who have an amenable mutation. Galafold is already approved in multiple geographies around the world, including the U.S., EU, and Japan, for adults who have an amenable variant, or mutation. The extension of the indication was supported by 1-month interim safety and pharmacokinetics data from Study AT1001-020 which was a 2-stage, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of migalastat treatment in pediatric subjects aged 12 to <18 years and weighing = 45 kg with Fabry disease and with amenable mutations to the gene encoding a-galactosidase A (GLA). The company will work closely with all relevant government authorities to secure access for eligible patients as quickly as possible. Galafold is not approved for adolescents outside of Europe.
Amicus Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021
2021-07-29 02:31:00
Amicus Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021. Venue: Carlsbad, California, United States. Presentation Date & Speakers: Oct-12-2021, Bradley L. Campbell, President, COO & Director. Oct-14-2021, Jamila Ritter, ARM GROW Intern.
Amicus Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
2021-07-27 11:00:00
Amicus Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
Amicus Therapeutics, Inc. to Report Q2, 2021 Results on Aug 05, 2021
2021-07-27 11:00:00
Amicus Therapeutics, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021
2021-07-01 10:09:00
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.
Amicus Therapeutics, Inc. Announces the Appointment of Daphne Quimi to its Board of Directors
2021-06-29 12:00:00
Amicus Therapeutics, Inc. announced the addition of Daphne Quimi to its Board of Directors. She currently serves as Chief Financial Officer (CFO) of Amicus Therapeutics.
Fundamental Summary
Amicus Therapeutics's financial results from Q1 demonstrated decent performance, but will likely only help Amicus Therapeutics remain on par with its peers. It is highly likely that the company will be mostly tethered to market performance and sector movements for the near term. Therefore, they earned a total score of 61 out of 100 and a HOLD recommendation.
Amicus Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 85.26 million compared to USD 65.66 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.25 a year ago.
Business Description
Amicus Therapeutics, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Sector Overview
Amicus Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Amicus Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -110.3 | -30.8% | 77 | |
| Net Cashflow | 49.8 | -40.2% | 81 | |
| Capital Expenditure | -3.9 | -0.1% | 71 | |
| Asset Turnover | 0.4 | 13.9% | 87 | |
| Free Cashflow | -0.7 | 8.8% | 80 |
* All values are TTM
The below chart reflects Amicus Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Amicus Therapeutics's peer average final assessment score stands on 64.0, Amicus Therapeutics's score is 61.
- FOLD
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Amicus Therapeutics's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Amicus Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.
5D MA
10.68
50D MA
8.0
200D MA
9.67
MACD
0.78
RSI
15.1
STOCH
83.95
Balance Sheet Analysis
Amicus Therapeutics's most recent balance sheet report has several troubling numbers, specifically Liabilities and Book Value Factors. At filing, Amicus Therapeutics's liabilities were 588.3, representing a -1.6% change from the previous period. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Its liabilities movement component, therefore, received a grade of 52. Also, Amicus Therapeutics publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 9.8 and represents -6.5% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 56. On the other hand, Cash & Equivalents, jumped out as looking rather positive. Amicus Therapeutics reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 233.3, representing -4.8% change from the last report. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. The company's cash and cash equivalents movement, therefore, received a grade of 66. Therefore, their balance sheet earned a grade of 56.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 826.9 | -8.6% | 64 |
| Liabilities | 588.3 | -1.6% | 52 |
| Price to Book | 9.8 | -6.5% | 56 |
| Cash & Equivalents | 233.3 | -4.8% | 66 |
| Equity | 238.6 | -22.4% | 58 |
The below chart describes Amicus Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Amicus Therapeutics received a balance sheet score of 56, the average of its peers stands on 63.0.
- FOLD
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 1 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 4 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 9 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 10 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 11 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 16 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 18 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Amicus Therapeutics's most recent income statement report was not encouraging. Amicus Therapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -201.5, which represents a -9.7% change from the last period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Therefore, their EBITDA component earned a score of 55. Also, Amicus Therapeutics management did an underwhelming job managing revenue efficiency this past period. Amicus Therapeutics's revenue efficiency is 317.8 according to the metrics in the current filing, which represents a 4.0% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Its revenue efficiency, therefore, received a grade of 61. On the other hand, Return Factors, jumped out as looking rather positive. Amicus Therapeutics's reported return on equity (ROE) ratio was -110.3, representing a change of -30.8%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Therefore, its return factors component earned a score of 77. The companie's income statement, therefore, earned a score of 58.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -201.5 | -9.7% | 55 |
| Total Revenues | 317.8 | 4.0% | 61 |
| Return on Equity | -110.3 | -30.8% | 77 |
The below chart describes Amicus Therapeutics's performance as reflected on its income statement with respect to its peers. While Amicus Therapeutics received a income statement score of 58 , the average of its peers stands on 65.0.
- FOLD
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 1 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 4 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 9 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 10 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 11 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 16 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 18 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Amicus Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Amicus Therapeutics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.4, representing a 13.9% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Therefore, its asset turnover movement earned a score of 87. Also, Amicus Therapeutics presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of 49.8, which is a change of -40.2% from the last filing. Their net cash flow metrics are especially remarkable relative to their peers. Hence, its net cash flow earned a score of 81. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Amicus Therapeutics's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -3.9, which represents a -0.1% change from the last period. This performance is all the more uninspiring relative to their peers and competitors. Consequently, their CapEx movement received a grade of 71. Its cash flow received an overall score of 85.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 49.8 | -40.2% | 81 |
| Capital Expenditure | -3.9 | -0.1% | 71 |
| Asset Turnover | 0.4 | 13.9% | 87 |
| Free Cashflow | -0.7 | 8.8% | 80 |
The below chart describes Amicus Therapeutics's performance as reflected on its cash flow with respect to its peers. While Amicus Therapeutics received a cash flow score of 85, the average of its peers stands on 71.0.
- FOLD
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 1 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 4 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 9 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 10 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 11 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 16 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 18 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.